Biogen’s Strategic Pivot: Focusing on Leqembi in the Fight Against Alzheimer’s
Biogen has announced the discontinuation of Aduhelm, its first Alzheimer’s treatment, to reallocate resources towards Leqembi, a newer drug that has shown promise in slowing the
